drugset / Trial / NCT03268811

A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302

NCT03268811

Phase 3 Completed 9 enrolled Shire Takeda · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical study is to evaluate the long-term safety and tolerability of teduglutide treatment in Japanese pediatric participants with short bowel syndrome (SBS) who completed Study SHP633-302 (NCT02980666).

Timeline

Start
2017-08-23
Primary completion
2021-11-02
Completion
2021-11-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Teduglutide Peptide 0.05 mg/kg Subcutaneous

Indications